{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cai H"],"funding":["NIH National Centre for Research Resources","Cancer Research UK","Leicester Experimental Cancer Medicine Centre","NCRR NIH HHS","NIGMS NIH HHS"],"pagination":["298ra117"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4827609"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(298)"],"pubmed_abstract":["Resveratrol is widely promoted as a potential cancer chemopreventive agent, but a lack of information on the optimal dose prohibits rationally designed trials to assess efficacy. To challenge the assumption that \"more is better,\" we compared the pharmacokinetics and activity of a dietary dose with an intake 200 times higher. The dose-response relationship for concentrations generated and the metabolite profile of [(14)C]-resveratrol in colorectal tissue of cancer patients helped us to define clinically achievable levels. In Apc(Min) mice (a model of colorectal carcinogenesis) that received a high-fat diet, the low resveratrol dose suppressed intestinal adenoma development more potently than did the higher dose. Efficacy correlated with activation of adenosine monophosphate-activated protei"],"journal":["Science translational medicine"],"pubmed_title":["Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice."],"pmcid":["PMC4827609"],"funding_grant_id":["P41 GM103483","P41 RR013461","C325/A13101","C325/A15575","P41RR13461","13101","#P41RR13461"],"pubmed_authors":["Rufini A","West K","Scott E","Karmokar A","Greaves P","Britton RG","Jawad D","Walsh J","Gescher AJ","Kholghi A","Cai H","Howells L","Goldring C","Steward WP","Horner-Glister E","James M","Hemingway D","Kitteringham N","Brown K","Andreadi C","Viskaduraki M","Malfatti M","Ognibene T","Miller A"],"additional_accession":[]},"is_claimable":false,"name":"Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.","description":"Resveratrol is widely promoted as a potential cancer chemopreventive agent, but a lack of information on the optimal dose prohibits rationally designed trials to assess efficacy. To challenge the assumption that \"more is better,\" we compared the pharmacokinetics and activity of a dietary dose with an intake 200 times higher. The dose-response relationship for concentrations generated and the metabolite profile of [(14)C]-resveratrol in colorectal tissue of cancer patients helped us to define clinically achievable levels. In Apc(Min) mice (a model of colorectal carcinogenesis) that received a high-fat diet, the low resveratrol dose suppressed intestinal adenoma development more potently than did the higher dose. Efficacy correlated with activation of adenosine monophosphate-activated protei","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2025-04-18T16:20:56.772Z","creation":"2019-03-27T03:11:44Z"},"accession":"S-EPMC4827609","cross_references":{"pubmed":["26223300"],"doi":["10.1126/scitranslmed.aaa7619"]}}